Glucose dendrimer-ketamine conjugates enable precise and efficacious neuromodulation while preserving neuronal network dynamics

Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using imageJ

10.3791/57648 · doi-reference

Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model

10.1016/s0014-4886(03)00086-4 · doi-reference

Modification of seizure activity by electrical stimulation. II. Motor seizure

10.1016/0013-4694(72)90177-0 · doi-reference

Loss of Protection by Antiepileptic Drugs in Lipopolysaccharide-primed Pilocarpine-induced Status Epilepticus is Mediated via Inflammatory Signalling

10.1016/j.neuroscience.2020.06.024 · doi-reference

Effect of lacosamide on neuroinflammation-mediated seizures comorbid with depression in C57BL/6 mice- Role of kynurenine pathway

10.1016/j.yebeh.2021.108262 · doi-reference

Intranasal administration of CNS therapeutics to awake mice

10.3791/4440-v · doi-reference

Factors affecting outcomes of pilocarpine treatment in a mouse model of temporal lobe epilepsy

10.1016/j.eplepsyres.2012.05.012 · doi-reference

Sex-related differences in glial fibrillary acidic protein-positive GABA regulate neuropathology following pilocarpine-induced status epilepticus

10.1016/j.neuroscience.2021.08.002 · doi-reference

Sex and hormonal influences on seizures and epilepsy

10.1016/j.yhbeh.2012.03.018 · doi-reference

Enhanced Stem Cell Differentiation and Immunopurification of Genome Engineered Human Retinal Ganglion Cells

10.1002/sctm.17-0059 · doi-reference

ER to synapse trafficking of NMDA receptors

10.3389/fncel.2014.00394 · doi-reference

Neuroimmunology of status epilepticus

10.1016/j.yebeh.2023.109095 · doi-reference

Complex alterations in microglial M1/M2 markers during the development of epilepsy in two mouse models

10.1111/epi.12960 · doi-reference

The role of inflammation in epilepsy

10.1038/nrneurol.2010.178 · doi-reference

Ketamine protects against pilocarpine-induced oxidative stress and metabolic enzyme disturbances during epileptogenesis in the epilepsy model

10.1007/s11094-024-03239-2 · doi-reference

Multi-electrode array technologies for neuroscience and cardiology

10.1038/nnano.2012.265 · doi-reference

Revealing neuronal function through microelectrode array recordings

10.3389/fnins.2014.00423 · doi-reference

Psychedelics promote structural and functional neural plasticity

10.1016/j.celrep.2018.05.022 · doi-reference

Norketamine, the Main Metabolite of Ketamine, Induces Mitochondria-Dependent and ER Stress-Triggered Apoptotic Death in Urothelial Cells via a Ca2+-Regulated ERK1/2-Activating Pathway

10.3390/ijms23094666 · doi-reference

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

10.1038/nature17998 · doi-reference

Glucose transporters: physiological and pathological roles

10.1007/s12551-015-0186-2 · doi-reference

Development of a novel glucose-dendrimer based therapeutic targeting hyperexcitable neurons in neurological disorders

10.1002/btm2.10655 · doi-reference

Targeted neuronal delivery of creatine using glucose dendrimer for creatine-transporter deficiency and neonatal brain injury

10.1007/s40883-025-00500-2 · doi-reference

Efficient intracellular delivery of CRISPR-Cas9 ribonucleoproteins using dendrimer nanoparticles for robust genomic editing

10.1016/j.nantod.2025.102654 · doi-reference

A new era in posterior segment ocular drug delivery: translation of systemic, cell-targeted, dendrimer-based therapies

10.1016/j.addr.2023.115005 · doi-reference

Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial

10.1126/scitranslmed.abo2652 · doi-reference

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity

10.1016/j.drudis.2016.01.016 · doi-reference

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

10.1177/2040622315579059 · doi-reference

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

10.1038/s41398-019-0624-1 · doi-reference

Attenuation of antidepressant effects of ketamine by opioid receptor antagonism

10.1176/appi.ajp.2018.18020138 · doi-reference

Ketamine: NMDA receptors and beyond

10.1523/jneurosci.1547-16.2016 · doi-reference

The abuse liability of ketamine: a scoping review of preclinical and clinical studies

10.1016/j.jpsychires.2022.04.035 · doi-reference

Ketamine abuse potential and use disorder

10.1016/j.brainresbull.2016.05.016 · doi-reference

Ketamine-Induced Hallucinations

10.1159/000438675 · doi-reference

Side-effects associated with ketamine use in depression: a systematic review

10.1016/s2215-0366(17)30272-9 · doi-reference

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions

10.1002/wps.21120 · doi-reference

Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials

10.1038/s41386-024-02044-5 · doi-reference

The role of ketamine in treatment-resistant depression: a systematic review

10.2174/1570159x12666140619204251 · doi-reference

Major depressive disorder: hypothesis, mechanism, prevention and treatment

10.1038/s41392-024-01738-y · doi-reference

Ketamine treatment for depression: a review

10.1007/s44192-022-00012-3 · doi-reference